The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
 
Andrea Wang-Gillam
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Jacobio; Merrimack; Vicus Therapeutics
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); CTI (Inst); EMD Serono (Inst); Halozyme (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); pfizer (Inst); Plexxikon (Inst); Precision Therapeutics (Inst); Roche (Inst); Verastem (Inst)
 
A. Craig Lockhart
Research Funding - Aduro Biotech (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CTI (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Lilly (Inst); Macrogenics (Inst); Millennium (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Teva (Inst); Vertex (Inst)
 
Benjamin R. Tan
Consulting or Advisory Role - Roche/Genentech
Research Funding - Bayer; Boehringer Ingelheim; Eisai; Exelixis; Lilly; Merck Serono; Pfizer; Roche/Genentech; Sillajen; tyrogenex
 
Rama Suresh
No Relationships to Disclose
 
Kian-Huat Lim
Stock and Other Ownership Interests - Merck
Research Funding - Confluence
 
Lee Ratner
No Relationships to Disclose
 
David G. DeNardo
No Relationships to Disclose